XML 19 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Net revenues $ 18,854 $ 22,385 $ 21,903
Cost of sales 10,558 11,770 10,250
Gross profit 8,296 10,615 11,653
Research and development expenses 1,213 1,778 2,077
Selling and marketing expenses 2,916 3,395 3,583
General and administrative expenses 1,298 1,451 1,390
Intangible assets impairments 1,991 3,238 589
Goodwill impairment 3,027 17,100 900
Other asset impairments, restructuring and other items 987 1,836 830
Legal settlements and loss contingencies (1,208) 500 899
Other income (291) (1,199) (769)
Operating (loss) income (1,637) (17,484) 2,154
Financial expenses-net 959 895 1,330
Income (loss) before income taxes (2,596) (18,379) 824
Income taxes (benefit) (195) (1,933) 521
Share in (profits) losses of associated companies-net 71 3 (8)
Net income (loss) (2,472) (16,449) 311
Net loss attributable to non-controlling interests (322) (184) (18)
Net income (loss) attributable to Teva (2,150) (16,265) 329
Accrued dividends on preferred shares 249 260 261
Net income (loss) attributable to ordinary shareholders $ (2,399) $ (16,525) $ 68
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (2.35) $ (16.26) $ 0.07
Diluted $ (2.35) $ (16.26) $ 0.07
Weighted average number of shares (in millions):      
Basic 1,021 1,016 955
Diluted 1,021 1,016 961